These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16944149)

  • 1. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration.
    Brown AP; Carlson TC; Loi CM; Graziano MJ
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):671-9. PubMed ID: 16944149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion.
    Huang W; Yang AH; Matsumoto D; Collette W; Marroquin L; Ko M; Aguirre S; Younis HS
    J Ocul Pharmacol Ther; 2009 Dec; 25(6):519-30. PubMed ID: 19929595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
    El-Hoss J; Cheng T; Carpenter EC; Sullivan K; Deo N; Mikulec K; Little DG; Schindeler A
    J Bone Joint Surg Am; 2014 Jul; 96(14):e117. PubMed ID: 25031379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10-plex quantitative proteomics and phosphoproteomics.
    Paulo JA; McAllister FE; Everley RA; Beausoleil SA; Banks AS; Gygi SP
    Proteomics; 2015 Jan; 15(2-3):462-73. PubMed ID: 25195567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.
    Ciuffreda L; Del Bufalo D; Desideri M; Di Sanza C; Stoppacciaro A; Ricciardi MR; Chiaretti S; Tavolaro S; Benassi B; Bellacosa A; Foà R; Tafuri A; Cognetti F; Anichini A; Zupi G; Milella M
    Neoplasia; 2009 Aug; 11(8):720-31. PubMed ID: 19649202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radio-sensitizing effect of MEK inhibition in glioblastoma in vitro and in vivo.
    Houweling M; Abdul UK; Brahm C; Lagerweij T; Heukelom S; Koken PW; Honeywell R; Wedekind LE; Peters GJ; Verheul H; Sminia P; Noske D; Wurdinger T; Westerman BA
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):297-305. PubMed ID: 36451044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems.
    Hennig M; Yip-Schneider MT; Wentz S; Wu H; Hekmatyar SK; Klein P; Bansal N; Schmidt CM
    Hepatology; 2010 Apr; 51(4):1218-25. PubMed ID: 20112426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.
    Ishida N; Fukazawa T; Maeda Y; Yamatsuji T; Kato K; Matsumoto K; Shimo T; Takigawa N; Whitsett JA; Naomoto Y
    Exp Cell Res; 2015 Jul; 335(2):197-206. PubMed ID: 25839409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901.
    Shannon S; Jia D; Entersz I; Beelen P; Yu M; Carcione C; Carcione J; Mahtabfar A; Vaca C; Weaver M; Shreiber D; Zahn JD; Liu L; Lin H; Foty RA
    BMC Cancer; 2017 Feb; 17(1):121. PubMed ID: 28187762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of ethylene glycol. II. Tissue distribution, dose-dependent elimination, and identification of urinary metabolites following single intravenous, peroral or percutaneous doses in female Sprague-Dawley rats and CD-1 mice.
    Frantz SW; Beskitt JL; Grosse CM; Tallant MJ; Dietz FK; Ballantyne B
    Xenobiotica; 1996 Nov; 26(11):1195-220. PubMed ID: 8948094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib).
    El-Hoss J; Kolind M; Jackson MT; Deo N; Mikulec K; McDonald MM; Little CB; Little DG; Schindeler A
    Bone; 2014 Feb; 59():151-61. PubMed ID: 24269278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression.
    Legrier ME; Yang CP; Yan HG; Lopez-Barcons L; Keller SM; Pérez-Soler R; Horwitz SB; McDaid HM
    Cancer Res; 2007 Dec; 67(23):11300-8. PubMed ID: 18056456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.
    LoRusso PM; Krishnamurthi SS; Rinehart JJ; Nabell LM; Malburg L; Chapman PB; DePrimo SE; Bentivegna S; Wilner KD; Tan W; Ricart AD
    Clin Cancer Res; 2010 Mar; 16(6):1924-37. PubMed ID: 20215549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of ethylene glycol. III. Plasma disposition and metabolic fate after single increasing intravenous, peroral, or percutaneous doses in the male Sprague-Dawley rat.
    Frantz SW; Beskitt JL; Tallant MJ; Zourelias LA; Ballantyne B
    Xenobiotica; 1996 May; 26(5):515-39. PubMed ID: 8736063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats.
    Srinivas NR; Shyu WC; Weiner RS; Warner G; Comereski C; Tay LK; Greene DS; Barbhaiya RH
    Pharm Res; 1997 Jul; 14(7):911-6. PubMed ID: 9244149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicology and carcinogenesis studies of a binary mixture of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (Cas No. 57465-28-8) and 2,3',4,4',5-pentachlorobiphenyl (PCB 118) (Cas No. 31508-00-6) in female Harlan Sprague-Dawley rats (gavage studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Nov; (531):1-218. PubMed ID: 17342196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NTP technical report on the toxicology and carcinogenesis studies of 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) (CAS No. 35065-27-1) in female Harlan Sprague-Dawley rats (Gavage studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 May; (529):4-168. PubMed ID: 16835634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [MAPK-ERK1/2 signaling pathway regulates osteogenic gene expression in rat osteoblasts in vitro].
    Ding D; Li L; Song Y; DU G; Wei X; Cao Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Oct; 33(10):1432-6. PubMed ID: 24144741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).
    Van Dort ME; Hong H; Wang H; Nino CA; Lombardi RL; Blanks AE; Galbán S; Ross BD
    J Med Chem; 2016 Mar; 59(6):2512-22. PubMed ID: 26943489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats.
    Han KS; Kim YG; Yoo JK; Lee JW; Lee MG
    Biopharm Drug Dispos; 1998 Nov; 19(8):493-500. PubMed ID: 9840211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.